Evidence map›Paper›PMID 39594831›Full record

ArticleCancers2024

Molecular and In Silico Analysis of the

Ozkan Ozdemir, Brittany L Bychkovsky, Busra Unal, Gizem Onder, Ufuk Amanvermez, Eylul Aydin, Berk Ergun, Ilayda Sahin, Merve Gokbayrak, Cansu Ugurtas and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Ozkan OzdemirDepartment of Medical Biology, School of Medicine, Acibadem University, 34752 Istanbul, Türkiye.ORCID 0000-0002-2647-6416
Brittany L BychkovskyDivision of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0001-7969-0603
Busra UnalDepartment of Medical Genetics, Division of Cancer Genetics, Umraniye Training and Research Hospital, 34764 Istanbul, Türkiye.ORCID 0000-0002-2056-2604
Gizem OnderRare Diseases and Orphan Drugs Application and Research Center (ACURARE), Acibadem University, 34752 Istanbul, Türkiye.ORCID 0000-0003-4933-8048
Ufuk AmanvermezRare Diseases and Orphan Drugs Application and Research Center (ACURARE), Acibadem University, 34752 Istanbul, Türkiye.ORCID 0000-0003-1037-6477
Eylul AydinRare Diseases and Orphan Drugs Application and Research Center (ACURARE), Acibadem University, 34752 Istanbul, Türkiye.ORCID 0009-0005-3982-5303
Berk ErgunGeniva Informatics and Health Services Incorporated Company, 34752 Istanbul, Türkiye.ORCID 0009-0007-0299-5549
Ilayda SahinRare Diseases and Orphan Drugs Application and Research Center (ACURARE), Acibadem University, 34752 Istanbul, Türkiye.ORCID 0000-0001-7347-5339
Merve GokbayrakDepartment of Medical Genetics, School of Medicine, Kocaeli University, 41001 Izmit, Türkiye.
Cansu UgurtasDepartment of Medical Genetics, School of Medicine, Kocaeli University, 41001 Izmit, Türkiye.ORCID 0000-0003-0605-1741
Merve Nur KorogluDepartment of Biostatistics and Bioinformatics, Health Sciences Institute, Acibadem University, 34752 Istanbul, Türkiye.ORCID 0009-0006-8305-4224
Berfin CakirDepartment of Genetics and Bioengineering, Istanbul Bilgi University, 34060 Istanbul, Türkiye.
Irem KalayDepartment of Medical Genetics, Division of Cancer Genetics, Umraniye Training and Research Hospital, 34764 Istanbul, Türkiye.ORCID 0000-0001-5873-7433
Naci CineDepartment of Medical Genetics, School of Medicine, Kocaeli University, 41001 Izmit, Türkiye.
Ugur OzbekRare Diseases and Orphan Drugs Application and Research Center (ACURARE), Acibadem University, 34752 Istanbul, Türkiye.
Huma Q RanaDivision of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Ozden Hatirnaz NgDepartment of Medical Biology, School of Medicine, Acibadem University, 34752 Istanbul, Türkiye.ORCID 0000-0001-7728-6527
Nihat Bugra AgaogluDivision of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0002-9336-0552

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cancer predispositioncheckpoint kinase 2 (CHEK2)statistically significant in silico predictor (SSIP)variant interpretationvariant of uncertain significance (VUS)

Identifiers

PMID39594831
PMCPMC11592704

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.